Loading clinical trials...
Loading clinical trials...
This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutat...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Mirati Therapeutics Inc.
NCT07222566 · Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, and more
NCT05777603 · Advanced Non Small Cell Lung Cancer
NCT06066138 · Locally Advanced Alveolar Soft Part Sarcoma, Metastatic Alveolar Soft Part Sarcoma, and more
NCT06731413 · Non-Small Cell Lung Cancer, NSCLC, and more
NCT07259226 · Advanced Breast Cancer, Advanced Gastric Cancer, and more
Local Institution - 012-898
Cerritos, California
City of Hope - Duarte (Main Campus)
Duarte, California
Local Institution - 012-898 D
Glendale, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions